Showing results (2421-2430 of 5,049) with videos related to

Sort By:
Pageof 505
Headache|May 23, 2024
Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy (MOTS) trialSamantha C Shao, Joseph Hentz, Patti Shank, et al.
Headache|May 27, 2024
Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraineRima M Dafer, Gretchen E Tietjen, John F Rothrock, et al.
Headache|May 24, 2024
A real-world prospective observational study of eptinezumab in Asian patients with migraineYi Jing Zhao, Jonathan Jia Yuan Ong, Sumit Kumar Sonu, et al.
Headache|June 26, 2024
Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headacheAndrew Blumenfeld, David Kudrow, Peter McAllister, et al.
Headache|June 26, 2024
The impact of updates in headache quality measures on adherence to best practices in a neurology resident clinic: A quality improvement studyRobert H Cascella, Christopher C Anderson, Enmanuel J Perez
Headache|June 26, 2024
Arachnoid granulations in idiopathic intracranial hypertension: Do they have an influence?Arndt-Hendrik Schievelkamp, Pia Wägele, Elke Hattingen
Headache|June 26, 2024
The location of pain in cluster headache: Data from the International Cluster Headache QuestionnaireLarry I Schor, Stuart M Pearson, Bruno de Castro Sousa, et al.
Headache|May 24, 2024
Machine learning identifies factors most associated with seeking medical care for migraine: Results of the OVERCOME (US) studySait Ashina, E Jolanda Muenzel, Robert A Nicholson, et al.
Headache|December 20, 2025
First successful protocol for desensitization to eptinezumabBenoit Gerard, Hubert Praudel, Michel Lanteri-Minet, et al.
Headache|December 30, 2025
Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trialNathaniel M Schuster, Mark S Wallace, Thomas D Marcotte, et al.
Pageof 505